Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study by Schoenenberger, Andreas W et al.
ORIGINAL PAPER
Thiamine supplementation in symptomatic chronic heart failure:
a randomized, double-blind, placebo-controlled, cross-over pilot
study
Andreas W. Schoenenberger • Renate Schoenenberger-Berzins •
Christoph Auf der Maur • Paolo M. Suter •
Athanasios Vergopoulos • Paul Erne
Received: 23 May 2011 / Accepted: 21 October 2011 / Published online: 5 November 2011
 Springer-Verlag 2011
Abstract
Background Diuretic treatment for heart failure may lead
to an increased urinary thiamine excretion and in long-term
thiamine deficiency, which may further compromise car-
diac function. This study evaluated the effect of high dose
thiamine supplementation in heart failure patients.
Methods Nine patients with diuretic treatment for symp-
tomatic chronic heart failure and a left ventricular ejection
fraction (LVEF)\40% were randomly assigned to receive
thiamine (300 mg/day) or placebo for 28 days. After a
wash-out of 6 weeks, the patients crossed-over to a second
treatment period. The primary outcome was a change in
LVEF.
Results Mean age was 56.7 ± 9.2 years (range 44.9–75.4
years). Baseline LVEF was similar for both treatment
groups (29.5% in the thiamine group and 29.5% in the
placebo group, P = 0.911). After 28 days of thiamine
treatment, the LVEF increased to 32.8% which was sig-
nificantly (P = 0.024) different from the LVEF in the
placebo group (28.8%). This corresponds to a treatment
effect for LVEF of 3.9% in absolute terms.
Conclusions This study suggests that thiamine supple-
mentation has beneficial effects on cardiac function in
patients with diuretic drugs for symptomatic chronic heart
failure. Subclinical thiamine deficiency is probably an
underestimated issue in these outpatients.
Keywords Thiamine  Heart failure  Diuretics 
Cross-over studies
Introduction
In the treatment of congestive heart failure, diuretic drugs
are a cornerstone of therapy. Up to 50% of an elderly
population in industrialized nations will undergo long-term
diuretic treatment [1]. Diuretic therapy is associated with
the loss of water soluble vitamins, including vitamin B1
(thiamine) [2–4]. A prospective hospital based study
reported that diuretic treatment is associated with an
increased risk for thiamine depletion [5]. Another study
reported that the prevalence of thiamine deficiency in
patients with heart failure was 33%, though many patients
were already taking thiamine supplements [6]. Thiamine is
an essential cofactor in energy metabolism and thus also
for normal cardiac function: thiamine deficiency is
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associated with the depression of myocardial function,
congestive heart failure and wet beriberi [7–9]. Therefore,
patients with congestive heart failure undergoing diuretic
treatment may additionally have a compromised heart
function due to thiamine deficiency.
So far, only three small studies examined the effect of a
thiamine supplementation on cardiac function [10–12].
Two of these studies, of which only one was randomized,
found an improvement of left ventricular function after
thiamine supplementation [10, 11]. However, in both these
studies patients had moderate to severe heart failure and
were inpatients on high doses of diuretics. The third study
did not find a significant effect of thiamine on the clinical
course of the cardiopathy, but cardiac function was not
assessed by echocardiography [12]. A recent study exam-
ined the effect of a micronutrient supplementation in
elderly patients with chronic heart failure, but the treatment
was not restricted to thiamine alone [13]. The study also
found a significant improvement of left ventricular func-
tion. We, therefore, intended to investigate the effect of
thiamine on cardiac function in outpatients with moderate
chronic heart failure in a randomized, controlled, double-
blind study using echocardiographic as well as clinical
endpoints.
Methods
Study population
All outpatients at the Lucerne Hospital, who were treated
with diuretics for symptomatic chronic heart failure, were
eligible for this study. Congestive heart failure was defined
as left ventricular ejection fraction (LVEF) below 40% and
the presence of at least one of the following four criteria:
(a) shortness of breath or orthopnea, (b) positive hepat-
ojugular reflex, (c) interstitial transudation on chest radi-
ography, or (d) elevated brain natriuretic peptide (BNP)
(C39 ng/L). Heart failure was considered stable if symp-
toms and body weight remained unchanged for at least
14 days. Patients with acute heart failure were not eligible
for this study because of the foreseeable need for further
changes in medication. Patients on vitamin supplements,
patients with renal failure (creatinine [250 lmol/L) and
fertile women were excluded from study participation.
Screening for eligibility was performed during routine
outpatient visits. Due to logistic reasons, screening for
eligibility of a new patient was started only after a previous
patient completed the study protocol. Informed written
consent was obtained from all eligible patients willing to
participate in the study. The study was approved by the
local ethical committee and complies with the Declaration
of Helsinki.
Intervention
A randomized, double-blind, placebo-controlled, two-per-
iod cross-over design was performed. The study coordi-
nation centre at the Bern University Hospital randomly
assigned participating patients to one of the two treatment
groups. The random allocation sequence was generated by
a computerized random number generator. The treatment
consisted of either thiamine (300 mg/day) or placebo
(1 tablet/day) for 28 days. Both preparations (thiamine and
placebo) were produced by the same company (Streuli
Pharmaceutical Company, Uznach, Switzerland) to ensure
identical size, shape and colour. The study coordination
centre at the Bern University Hospital provided the allo-
cated treatment in sequentially numbered containers to the
care providers at the Lucerne Hospital. By separating the
randomization centre (Bern University Hospital) and
examination site (Lucerne Hospital), participating patients
and physicians assessing outcomes were blinded to the
treatment allocation.
The first treatment period of 28 days was followed by a
wash-out period of 6 weeks to eliminate any carry-over
effects. After the wash-out, the patient was enrolled for the
second treatment period. The second treatment period was
identical to the first, except for the medication which was
reversed (placebo or thiamine).
Prescriptions for other medications were continued
throughout the study. A change in medication was allowed
whenever it was required by clinical circumstances.
Examinations and follow-up
Patients were examined on days 1, 8, 15 and 29 of each
treatment period. Treatment with either thiamine or placebo
was started on day 2. Functional status (general health,
dyspnea during day, night and exercise) was assessed on
days 1, 8, 15 and 29 using visual analogue scales. A 6-min
walking test was performed on days 1, 8, 15 and 29. In this
test, patients had to walk on a predefined route for 6 min
and the distance walked was recorded (in m). Assessment of
functional status was completed by a 24-h steps counter
(pedometer) at home on days 2, 3, 27 and 28. Dietary intake
at home was recorded on a protocol on days 2, 3 and 4. BNP
was measured on days 1, 8, 15 and 29. Creatinine, potas-
sium, sodium, magnesium, ferritin and haemoglobin were
measured on days 1 and 29. Free thiamine was measured on
days 1, 8, 15 and 29 by high-pressure liquid chromatogra-
phy (normal range 28–85 ng/mL). An ECG was recorded
on days 1 and 29. Transthoracic echocardiography was
performed on days 1, 8, 15 and 29 by the same operator.
LVEF was determined on two- and four-chamber views
using the modified biplane Simpson method. The operator
was blinded for the treatment.
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Outcomes
The primary interest of the study was a change in echo-
cardiographic findings, particularly the LVEF. Other out-
comes were functional status as assessed by visual
analogue scales, the 6-min walking test, pedometer steps
and the level of B-type natriuretic peptide.
Statistical methods
Sample size was calculated supposing a relative increase of
the LVEF of 6% and a standard deviation of the LVEF of
7% [11]. With an alpha-error of 0.05 and a power of 0.80, a
sample size of 22 was found for a parallel group design. It
is presumed that with the cross-over design, the total
number of subjects is lower than half (probably one quar-
ter) of the total number required for a parallel group study
with the same power.
Data were analysed using Stata software (Stata 11.0,
StataCorp LP, College Station, TX, USA). A P value\0.05
was considered significant. For two-group comparisons,
paired t test was used after checking for normal distribu-
tion; Mann–Whitney rank-sum test was used for non-nor-
mally distributed continuous variables. An analysis of
variance was performed to confirm the effect of the treat-
ment on LVEF.
Results
Of 16 eligible patients, 6 (37.5%) patients declined par-
ticipation due to refusal to take an additional drug or
inability to come to the frequent follow-up examinations
(Fig. 1). Between 18 June 2004 and 21 May 2008, ten
patients were randomized to thiamine or placebo and
completed the first treatment period. One patient withdrew
his consent during the wash-out period because he was no
longer willing to travel the distance to the hospital for the
frequent follow-up examinations. Therefore, nine patients
completed the second treatment period and were included
in the analysis.
The baseline characteristics of the nine participating
patients are shown in Table 1. The mean age was
56.7 ± 9.2 years (range 44.9–75.4 years). As a cause for
reduced LVEF and heart failure, coronary artery disease
(CAD) was found in six patients (67%) and dilative car-
diomyopathy in three patients (33%). Dilative cardiomy-
opathy was related to excess alcohol consumption in one
patient and was of unknown origin in two patients. In both
patients, CAD was excluded by angiography. CAD was
combined with valvular and hypertensive heart disease in
one patient. All patients had a prescription for an angio-
tensin-converting enzyme inhibitor or an angiotensin
receptor blocker and a diuretic. The prescriptions for
medications other than thiamine or placebo remained
unchanged throughout the study in all patients except for
one patient in whom the dose of the diuretic drug was
temporarily increased due to swollen legs.
During thiamine treatment, free thiamine increased from
73 ± 10 ng/mL (range 60–91 ng/mL) on day 1 to
132 ± 29 ng/mL (range 102–199 ng/mL) on day 8
(P \ 0.001). The percentage increase between day 1 and
day 8 in the individual patient was minimally 140% and
maximally 219%. During thiamine treatment, free thiamine
remained on a high level on days 15 and 29 (133 ± 28 ng/
mL and 132 ± 33 ng/mL, respectively). No increase in
free thiamine was observed during placebo treatment.
Compliance with the prescribed treatment was therefore
100%.
In the five patients having received thiamine during the
first treatment period, free thiamine decreased to
75 ± 4 ng/mL (range 70–81 ng/mL) at day 1 of the second
treatment period. The LVEF in these five patients also
decreased from 33.8% at last follow-up during the first
treatment period to 30.6% at the beginning of the second
treatment period. A relevant period effect was, therefore,
excluded and both treatment periods were combined for the
analysis of outcomes.
Fig. 1 Patient flow
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Outcomes
Results of main outcomes at first assessment on day 1
and last follow-up on day 29 of both cross-over treat-
ment periods combined during thiamine or placebo
treatment are summarized in Table 2. At baseline (first
assessment on day 1), outcome variables were similar
between thiamine and placebo group with no significant
differences between the two treatment groups. The main
finding was that LVEF was significantly different
between the thiamine and the placebo group at last fol-
low-up on day 29 (32.8% with thiamine and 28.8% with
placebo, P = 0.024) (Fig. 2). This corresponds to a
treatment effect for LVEF of 3.9% in absolute terms. For
the other outcomes, no significant differences were found
at the last follow-up for the between-treatment group
comparison. However, the 24-h steps counter measure-
ment showed a nearly significant improvement during
thiamine treatment.
In addition to the between-treatment group comparisons
in Table 2, the change of the outcomes between day 1 and
day 29 within each treatment group was analyzed. The
LVEF increase during thiamine from 29.5 to 32.8% was
significant (P = 0.015). The decrease of the right atrium
area during thiamine from 16.7 to 14.8 cm2 was significant
(P = 0.026). The improvement of the 6-min walking test
from 549 to 624 m was close to significance during thia-
mine treatment (P = 0.084). No significant changes in
outcomes between baseline and follow-up assessment were
found during placebo treatment.
An analysis of variance was performed to confirm the
effect of the treatment on LVEF. As dependent variable the
change in LVEF between first and last follow-up was
chosen. Age, sex, the presence of a CAD or dilative car-
diomyopathy, and the treatment (thiamine or placebo) were
selected as independent variables. Of these variables, only
the treatment had a significant effect on the change in
LVEF (F ratio = 6.09, P = 0.028).
Discussion
This study shows that a treatment with 300 mg thiamine
per day improves cardiac function as measured by echo-
cardiography in patients, who were treated with diuretics
for symptomatic chronic heart failure. In particular, LVEF
improves with thiamine. The improvement of cardiac
function probably has beneficial effects on functional status
as measured by the 6-min walking test and the 24-h steps
counter.
Our study is in agreement with the two previous studies
that found an improvement of left ventricular function after
thiamine supplementation [10, 11]. In addition to these
studies, our study shows that the improvement of heart
function may also be achieved in patients with symptom-
atic chronic heart failure and that this improvement prob-
ably has a beneficial effect on functional status.
The study was performed in a two-period cross-over
design. This design was selected because the interindivid-
ual variability of the measured outcomes was expected to
be high in comparison to the beneficial effect of the
treatment in the individual patient. Consequently, a cross-
over design was more efficient than a parallel group design.
Table 1 Baseline characteristics
Characteristics Study participants
(N = 9)
Age, mean ± SD (years) 56.7 ± 9.2
Female sex, n (%) 2 (22)
Weight, mean ± SD (kg) 81 ± 18
Height, mean ± SD (cm) 173 ± 9
Body mass index, mean ± SD (kg/m2) 27 ± 6
Blood pressure systolic, mean ± SD
(mmHg)
122 ± 18
Blood pressure diastolic, mean ± SD
(mmHg)
74 ± 12
Heart rate, mean ± SD (beats/min) 74 ± 14
Creatinine, mean ± SD (lmol/L) 100 ± 23
Cardiovascular risk factorsa
Hypertension, n (%) 4 (44)
Dyslipidemia, n (%) 6 (67)
Diabetes, n (%) 1 (11)
Smoking, n (%) 6 (67)
Family history of CAD, n (%) 3 (33)
Heart diseaseb
CAD, n (%) 6 (67)
Valvular heart disease, n (%) 1 (11)
Hypertensive heart disease, n (%) 1 (11)
Dilative cardiomyopathy, n (%) 3 (33)
Signs of heart failure
Dyspnea or orthopnea, n (%) 7 (78)
Hepatojugular reflex positive, n (%) 0 (0)
Interstitial transudation on chest
radiography, n (%)
0 (0)
BNP elevated (C39 ng/L), n (%) 5 (56)
Drug therapy
ACE inhibitor or ARB, n (%) 9 (100)
Loop or thiazid diuretic, n (%) 8 (89)
Aldosterone antagonist, n (%) 4 (44)
Beta blocker, n (%) 8 (89)
ACE angiotensin-converting enzyme, ARB angiotensin receptor
blocker, BNP brain natriuretic peptide, CAD coronary artery disease,
SD standard deviation
a Definition according to international guidelines
b More than one diagnosis per patient allowed
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For thiamine, a pharmacological dose of 300 mg/day was
selected. Although this dosage exceeds daily requirement
by far, a high dosage was considered essential to guarantee
a measurable effect. In view of the characteristics of thia-
mine metabolism, a wash-out period of 6 weeks was con-
sidered adequate for the elimination of a carry-over effect.
The thiamine and LVEF measurements at the beginning of
the second treatment period in the five patients having
received thiamine during the first treatment period con-
firmed that a wash-out period of 6 weeks was sufficient.
This study has several limitations. First, the sample size
of nine patients is very small and the follow-up period was
comparatively short. It was too small to show significant
differences between the treatment groups for other out-
comes than LVEF [14]. However, a significant effect of
thiamine on these outcomes may not be expected,
according to the a priori sample size calculation. Due to the
short follow-up periods, we cannot estimate the effect of
thiamine on further important outcomes such as mortality
or morbidity [15–18]. Therefore, our study only suggests
potential usefulness of thiamine which needs to be con-
firmed in a larger study. Second, the thiamine dose was in
the pharmacological range since the vitamin was given as a
drug and not as a nutritional supplement. In future studies
dose–response effects need to be assessed. Third, we
measured free thiamine which was within normal range on
day 1 (normal range 28–85 ng/mL). However, free thia-
mine levels may be normal despite subclinical thiamine
deficiency. For the assessment of subclinical thiamine
deficiency measurement of enzymatic activity (such as the
transketolase activity) would have been more appropriate
[5].
The authors believe that this study has research impli-
cations. Larger and longer studies investigating potential
beneficial and also harmful effects of thiamine in patients
with symptomatic chronic heart failure, but also in patients
with acute heart failure, are required. In due consideration
of the beneficial effects found in this and the previous small
studies, the clinical implications of a large study potentially
are crucial [10, 11]. However, it is too early to derive
clinical implications from this pilot study. Furthermore, it
would be interesting to examine the effect of thiamine
Table 2 Results of main outcomes at first assessment on day 1 and last follow-up on day 29 of both cross-over treatment periods combined and
separated for each treatment group (thiamine and placebo)
Outcomes At first assessment (day 1) of both treatment
periods combined
At last follow-up (day 29) of both treatment
periods combined
Thiamine
(N = 9)
Placebo
(N = 9)
P valuea Thiamine
(N = 9)
Placebo
(N = 9)
P valuea
Dyspnea during day, mean ± SE, VASb 1.9 ± 0.8 2.2 ± 0.9 0.963 1.5 ± 0.8 1.7 ± 0.9 0.617
Dyspnea during night, mean ± SE, VASb 0.7 ± 0.7 0.8 ± 0.8 0.634 0.8 ± 0.8 0.6 ± 0.5 0.634
Weight, mean ± SE (kg) 81 ± 6 81 ± 6 0.791 80 ± 6 80 ± 6 0.782
6-min walking test, mean ± SE (m) 549 ± 31 605 ± 28 0.157 624 ± 28 614 ± 24 0.689
24-h steps counter, mean ± SE (steps/day) 7052 ± 1529 6596 ± 1337 0.930 8596 ± 1270 5944 ± 1069 0.089
BNP, mean ± SE (ng/L) 166 ± 71 183 ± 86 0.508 165 ± 72 170 ± 64 0.402
LVEF, mean ± SE (%) 29.5 ± 2.4 29.5 ± 2.5 0.911 32.8 ± 2.7 28.8 ± 2.4 0.024
LVEDV, mean ± SE (mL) 197 ± 25 194 ± 30 0.757 188 ± 36 169 ± 24 0.560
Area of left atrium, mean ± SE (cm2) 22.2 ± 1.4 21.2 ± 1.8 0.442 21.0 ± 1.2 21.3 ± 1.8 0.871
Area of right atrium, mean ± SE (cm2) 16.7 ± 1.0 17.3 ± 1.8 0.780 14.8 ± 0.7 15.9 ± 1.2 0.289
Thickness of IVS, mean ± SE (mm) 8.9 ± 0.3 9.0 ± 0.4 0.786 9.4 ± 0.3 8.7 ± 0.4 0.215
BNP brain natriuretic peptide, IVS interventricular septum, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction,
SE standard error, VAS visual analogue scale
a P value for the between-treatment group comparison
b Dyspnea measured by visual analogue scales (range from 0 for no dyspnea to 10 for maximal dyspnea)
Fig. 2 Changes in the left ventricular ejection fraction (LVEF)
between first assessment on day 1 and last follow-up on day 29
according to treatment group (thiamine or placebo). Mean LVEF as
well as LVEF of individual patients is displayed
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supplementation in patients with diuretic resistance. Future
studies should also examine very old patients as the inci-
dence of congestive heart failure, thiamine malnutrition
and diuretic treatment increases with age [19–22].
In conclusion, this study shows that the thiamine sup-
plementation has beneficial effects on cardiac function in
patients with symptomatic chronic heart failure. In view of
the safety profile of thiamine, a therapeutic thiamine trial in
difficult to treat patients with congestive heart failure
seems to be warranted and timely.
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